Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10159666 Dosing of cabozantinib formulations

Patent 10159666 was granted and assigned to Exelixis Ltd on December, 2018 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

All edits

Edits on 21 Aug, 2024

"update inverses"

Golden AI

edited on 21 Aug, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 12064430 Kinase inhibitor salts and compositions thereof

Edits on 8 Dec, 2023

"Add patent abstract"

Golden AI

edited on 8 Dec, 2023

Edits made to:

Article (+319 characters)

Article

Patent abstract

The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.

Edits on 20 Sep, 2023

"update inverses"

Golden AI

edited on 20 Sep, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11760726 Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Edits on 22 Apr, 2023

"Entity importer update"

Golden AI

edited on 22 Apr, 2023

Infobox

Is a

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

101596660

Date of Patent

December 25, 2018

Patent Application Number

151267670

Date Filed

March 17, 2015

Patent Citations Received

‌

US Patent 10501418 Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

‌

US Patent 10851061 Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

‌

US Patent 11065240 Drug combinations to treat multiple myeloma

‌

US Patent 11564915 Cabozantinib dosage form and use in the treatment of cancer

Patent Primary Examiner

‌

Taofiq A. Solola

Edits on 31 Mar, 2023

"update citations for inverse infoboxes"

Golden AI

edited on 31 Mar, 2023

Infobox

Patent Citations Received

‌

US Patent 10501418 Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Edits on 29 Mar, 2023

"update citations for inverse infoboxes"

Golden AI

edited on 29 Mar, 2023

Infobox

Patent Citations Received

‌

US Patent 11564915 Cabozantinib dosage form and use in the treatment of cancer

Edits on 24 Mar, 2023

"update citations for inverse infoboxes"

Golden AI

edited on 24 Mar, 2023

Infobox

Patent Citations Received

‌

US Patent 11065240 Drug combinations to treat multiple myeloma

Edits on 22 Mar, 2023

"update citations for inverse infoboxes"

Golden AI

edited on 22 Mar, 2023

Infobox

Patent Citations Received

‌

US Patent 10851061 Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Edits on 1 Feb, 2023

"update inverses"

Golden AI

edited on 1 Feb, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11564915 Cabozantinib dosage form and use in the treatment of cancer

Edits on 28 Sep, 2022

"Entity importer update"

Golden AI

edited on 28 Sep, 2022

Infobox

Is a

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

101596660

Date of Patent

December 25, 2018

Patent Application Number

151267670

Date Filed

March 17, 2015

Patent Citations Received

‌

US Patent 10501418 Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

‌

US Patent 10851061 Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

‌

US Patent 11065240 Drug combinations to treat multiple myeloma

Patent Primary Examiner

‌

Taofiq A. Solola

Edits on 26 Sep, 2022

"update citations for inverse infoboxes"

Golden AI

edited on 26 Sep, 2022

Infobox

Patent Citations Received

‌

US Patent 11065240 Drug combinations to treat multiple myeloma

Edits on 22 Sep, 2022

"update citations for inverse infoboxes"

Golden AI

edited on 22 Sep, 2022

Infobox

Patent Citations Received

‌

US Patent 10851061 Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Edits on 13 Feb, 2022

"update inverses"

Golden AI

edited on 13 Feb, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Patent citations received

‌

US Patent 11065240 Drug combinations to treat multiple myeloma

Edits on 8 Feb, 2022

"update inverses"

Golden AI

edited on 8 Feb, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Patent citations received

‌

US Patent 10851061 Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Edits on 31 Jan, 2022

"update inverses"

Golden AI

edited on 31 Jan, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Patent citations received

‌

US Patent 10501418 Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Edits on 24 Jan, 2022

"Created via: Entity Importer"

Golden AI

created this topic on 24 Jan, 2022

Edits made to:

Infobox (+9 properties)

‌